Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002150 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
A Phase 2 study of HIV Infections, sponsored by Hoechst Marion Roussel.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT00002150: Completed Phase 2 study of HIV Infections, sponsored by Hoechst Marion Roussel.
NCT00002150 is a Phase 2 study of HIV Infections that has completed, run by Hoechst Marion Roussel. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002150, a Phase 2 study of HIV Infections, has completed, sponsored by Hoechst Marion Roussel.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection. To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A alone and in combination with AZT.
Conditions Studied
Interventions
- DRUG Celgosivir hydrochloride
Study Locations (20)
Florida
- Community Research Initiative of South Florida - Coral Gables
- Independent Investigator - Fort Lauderdale
- North Broward Hosp District - Fort Lauderdale
- Clinical Research Ctr - Sarasota
- Independent Investigator - Vero Beach
California
- California Clinical Trials Med Group - Beverly Hills
- Southwest Community Based AIDS Treatment Group - COMBAT - Los Angeles
- UCSF - San Francisco Gen Hosp - San Francisco
New York
- Community Health Network - Rochester
- SUNY / Health Sciences Ctr at Stony Brook - Stony Brook
Alabama
- Clinical Investigations Health Services - Mobile
District of Columbia
- George Washington Univ / Hershey Med Ctr - Washington D.C.
Illinois
- Ctr for Special Immunology - Chicago
Indiana
- Indiana Univ Hosp - Indianapolis
Kansas
- Univ of Kansas School of Medicine - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Phase | Phase 2 |
What the finished NCT00002150 record still lists
NCT00002150 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Celgosivir hydrochloride is the first listed.
NCT00002150 names 20 study sites across 13 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT00002150 about?
NCT00002150 is a clinical study titled "A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients". To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection. To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A...
What is the current status of trial NCT00002150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants.
What conditions does trial NCT00002150 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002150?
The interventions under investigation include: Celgosivir hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002150?
This trial is sponsored by Hoechst Marion Roussel, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002150 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002150's enrollment target sits among peer trials
200 171st of 542 higher than 362 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes